Supplementary data: Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada

Sender Herschorn, Jameel Nazir, Barbara Ramos, Zalmai Hakimi

Abstract


N/A

Full Text:

PDF


DOI: http://dx.doi.org/10.5489/cuaj.4617

Comments on this article

View all comments
 |  Add comment